FHTX Similar Chart Price Prediction
The price of FHTX is predicted to go up 11.93%, based on the high correlation periods with PANL. The similarity of these two price pattern on the periods is 97.68%.
FHTX
PANL
Up: 11.93%Similarity: 97.68%
FHTX Revenue Forecast
FHTX EPS Forecast
FHTX FAQs
What is bull’s view on FHTX?
What is bear's view on FHTX?
What is FHTX revenue forecast for next quarter？
What is FHTX eps forecast for next quarter？
FHTX Analyst's Forecast
Kalpit Patel
B. Riley Securities
Strong Buy
2025-01-30
Price Target
$10
Upside
+130.41%
B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers on the company's strategy to inactivate or degrade SMARCA2 in SMARCA-mutated cancers, "representing a potentially significant market opportunity" accounting for 5% of all solid tumors. The analyst views Foghorn's lead asset, FHD-909, a selective SMARCA2 inhibitor currently in a Phase I dose-escalating study, as the primary value driver. Despite FHD-909's key differentiated attributes and robust preclinical data, the Street is undervaluing the program due to disappointing early efficacy data from Prelude Therapeutics' (PRLD) SMARCA2 degrader, the analyst tells investors in a research note. Riley says the pullback has created an attractive entry point to buy Foghorn shares.
Vikram Purohit
Morgan Stanley
Hold
2024-09-24
Price Target
$6 → $9
Downside
-5.86%
